Sessions will focus on current advances in stem cell transplantation and cancer cell therapy, and emerging applications of these novel therapies in hematologic disorders and solid tumors.

Komen is the largest nonprofit funder of breast cancer research outside of the U.S. government, having invested more than $1.1 billion in research since its founding.

Three-time leukemia survivor is expecting child

When there’s no standard treatment, doctor elevates care

Patient’s story details the challenges of early-onset cancer diagnosis

Patient with melanoma receives tumor-infiltrating lymphocyte therapy

Circulating tumor DNA holds hope for personalizing breast cancer care